Market Overview

BioMarker Strategies Announces that Both of Its Core Diagnostics Technologies for Solid Tumor Cancers Are Now Covered by New Patents Granted in Canada

Share:

"Improved Methods and Devices for Cellular Analysis" (CA2703631)
covers the SnapPath® Cancer Diagnostics System technology

"Compositions and Methods for Prediction of Drug Sensitivity,
Resistance, and Disease Progression" (CA2795362) covers PathMAP®
Functional Signaling Profile technology

BioMarker Strategies LLC today announced that the Canadian Patent Office
has granted new patents covering its SnapPath® Cancer Diagnostics System
technology and its PathMAP® Functional Signaling Profile technology.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180328005229/en/

The SnapPath® Cancer Diagnostics System is the only diagnostics system that can generate purified po ...

The SnapPath® Cancer Diagnostics System is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. SnapPath preserves the molecular integrity of these living cells for exposure outside the human body to targeted therapies. This enables the generation of PathMap® Functional Signaling Profiles, which are highly predictive of individual solid tumor response to targeted therapies and combinations, because they are based on the dynamic, predictive signaling information available only from live cells. BioMarker Strategies has been granted patents on both of these important technologies in the United States, Europe, Australia, Canada and Japan, and patent applications are pending elsewhere. (Photo: Business Wire)

"Patents on both of our core technologies have now been granted in the
United States, Europe, Australia, Canada and Japan," said Jerry Parrott,
President and CEO, BioMarker Strategies. "These and other granted
patents give us broad protection to advance our mission to enable the
use of live cells to personalize drug development and treatment
selection for patients with solid tumor cancers."

SnapPath is the only diagnostics system that can generate purified
populations of live solid tumor cells from live, unfixed samples in an
automated and standardized manner. The system preserves the molecular
integrity of these living cells for ex vivo exposure to targeted
therapies. This enables the generation of PathMap Functional Signaling
Profiles, which are highly predictive of individual solid tumor response
to targeted therapies and combinations, because they are based on the
dynamic, predictive signaling information available only from live cells.

"The dynamic information available only from live cells is required to
understand initial response and the acquired resistance that too often
develops in the treatment of cancer," said Mr. Parrott. "This
understanding is necessary for accurate prediction of individual
response to targeted treatment of solid tumors."

Patents Granted BioMarker Strategies for Its SnapPath® Cancer
Diagnostics System: "Improved Methods and Devices for Cellular Analysis"

Country/Region

 

Patent #

 

Issue Date

 

Expiration

United States US9121801 September 1, 2015 December 28, 2030
Europe EP2210080 January 28, 2015 October 24, 2028
Australia AU2008317329 January 15, 2015 October 24, 2028
Australia AU2014277688 January 19, 2017 October 24, 2028
Canada CA2703631 August 22, 2017 October 24, 2028
Hong Kong HK1145878 August 14, 2015 October 24, 2028
Japan JP6177841 July 21, 2017 October 24, 2028
Korea KR10-1658245 September 9, 2016 October 24, 2028
 

Patents Granted for the Company's PathMAP® Functional Signaling
Profile Technology: "Compositions for Prediction of Drug Sensitivity,
Resistance and Disease Progression"*

Country/Region

 

Patent #

 

Issue Date

 

Expiration

United States US9766249 September 19, 2017 August 31, 2025
Europe EP2561368 August 2, 2017 April 18, 2031
Australia AU2011242990 May 28, 2015 April 18, 2031
Canada CA2795362 March 20, 2018 April 18, 2031
Japan JP6158078 June 16, 2017 April 18, 2031
Singapore SG184507 May 6, 2015 April 18, 2031

*Also officially allowed and proceeding to granted patent in China.

 

The SnapPath and PathMAP technologies are ideally suited to assess
response to targeted drugs in development for the treatment of solid
tumor cancers. BioMarker Strategies' current business development
efforts are directed primarily toward providing research services to
companies developing targeted drugs and combinations for the treatment
of patients with these cancers. The Company expects to enter into its
first commercial research services agreements in 2018.

About BioMarker Strategies

BioMarker Strategies is a privately-held molecular diagnostics company
founded in 2006 at The Johns Hopkins Science & Technology Park in
Baltimore, and now based in Rockville, Maryland. Our mission is to help
make personalized medicine more of a reality for patients with solid
tumor cancers, by providing powerful new molecular tools and research
services to guide targeted drug development and treatment selection. For
more information about BioMarker Strategies, please see www.biomarkerstrategies.com.

Forward-Looking Statements

The information in this press release includes our projections and other
forward-looking statements regarding future events. In some cases,
forward-looking statements may be identified by terminology such as
"may," "will," "should," "expects," "intends," "plans," "anticipates,"
"believes," "projects," "estimates," "predicts," "potential,"
"continue", etc. These statements are not guarantees of future
performance or achievement and involve certain risks and uncertainties,
which are difficult to predict. Therefore, actual future results and
trends may differ materially from what is projected here.

View Comments and Join the Discussion!